Covid | 'Oxford vaccine's late stage trials to start in a week in India': ICMR
At present country has three Indian COVID-19 vaccines which are in different phases of clinical testing, said Indian Council of Medical Research (ICMR) Director General Dr Balram Bhargava on Tuesday.
Addressing a press conference in the national capital, he said, "At the present moment, we have three Indian vaccines which are in different phases of clinical testing.
The 2 vaccines- Bharat Biotech vaccine and DNA vaccine of Zydus Cadila have completed phase 1 and will begin phase 2 while third is Oxford vaccine." "Oxford vaccine, being manufactured by Serum Institute of India (SII) got approval for phase 2 and 3 clinical trials, which are starting within a week at 17 sites," he added.
Dr Bhargava, however, said that social distancing and proper hygiene are the best "vaccine" available now and even after.
"Physical Distancing, wearing a mask, proper hand hygiene are the best vaccine available at the moment and even after.
We will have to continue with these measures," he said.
India has so far recorded over 18 lakh cases and more than 38,900 deaths.
Indian Council of Medical Research Director General Balram Bhargava on September 29 said that 5-T strategy (Test, Track, Trace, Treat and Technology is to adhered to contain spread of COVID-19. "Since a large portion of the population is yet susceptible, prevention fatigue is to be avoided and 5-T strategy (Test, Track, Trace, Treat and Technology) is to be adhered," said Bhargava on Second Sero-survey.
Indian Council of Medical Research Director General Balram Bhargava on September 29 said that urban slum and urban non-slum areas had higher SARS_CoV_2 infection prevalence than that of rural areas. "As per ICMR's (Indian Council of Medical Research) second sero survey report, urban slum and urban non-slum areas had higher SARS_CoV_2 infection prevalence than that of rural areas," Bhargava added.
Director General of the Indian Council of Medical Research (ICMR), Dr Balram Bhargava said three vaccine candidates are at different clinical trial stages in India. Covid-19 vaccine candidates being manufactured by Cadila Healthcare and Bharat Biotech have completed the first phase of the trial while the Serum Institute of India (SII) will begin with Phase 3 trial after getting the nod, Balram Bhargava, ICMR’s director general, said during the health ministry’s briefing.The Pune-based Serum Institute will conduct the Phase 3 trial on 1,500 volunteers across 14 locations, Bhargava added.
Credit: HT Digital Content Duration: 01:19Published
With a spike of 80,472 new cases, India's COVID-19 tally has crossed 62-lakh mark on September 30. Total case tally now stands at 62,25,764 including 9,40,441 active cases, 51,87,826 cured/discharged/migrated. The total number of deaths from the disease in the country mounts at 97,497. According to Indian Council of Medical Research (ICMR), A total of 7,41,96,729 samples tested for COVID, up to 29th September. Of these, 10,86,688 samples were tested yesterday.
Director General of Indian Council of Medical Research, Balram Bhargava on September 15 informed about the COVID-19 vaccines trial stage in India. He said, Cadila and Bharat Biotech have completed phase-I trials and Serum Institute has completed phase II-B3 trials, and will start phase-III trials after clearance. He said, "3 vaccines are at clinical trial stage in India. Cadila and Bharat Biotech have completed phase-I trials. Serum Institute has completed phase II-B3 trials, and will start phase-III trial (with 1500 patients at 14 locations) after clearances."
Indian Council of Medical Research, Director General Dr. Balram Bhargava during Health Ministry's briefing on COVID-19 situation in India informed about the sero survey publication. Bhargava said, "ICMR sero survey is publication in-progress. It should appear by this week in the Indian Journal of Medical Research. It has been peer reviewed. The second national sero-survey should be completed in the first week September". On situation of COVID-19 vaccines in India, Balram Bhargava said, "Three COVID-19 vaccines are ahead in the race in India. Serum Institute's vaccine is in phase 2(B) and phase 3 trials and Bharat Biotech and Zydus Cadila's vaccines have completed phase 1 trial."
From another minister in the Narendra Modi cabinet testing positive for infection, to the progress report of India's indigenously-developed vaccine candidates - here are the top news updates on the Covid-19 pandemic. Union minister of petroleum and natural gas, and steel, Dharmendra Pradhan, tested positive days after Union Home minister Amit Shah confirmed his positive diagnosis. Meanwhile, other members of the Union cabinet, like Ravi Shankar Prasad and Babul Supriyo, are quarantining themselves as a precaution. On the medical front, India's two vaccine candidates have completed phase 1 of human clinical trials. The vaccines have been developed by Bharat Biotech, ICMR and Zydus Cadila. The Jammu and Kashmir administration has decided to allow all places of worship to reopen from August 16. Earlier, the authorities had decided to cancel the annual Amarnath Yatra due to the Covid pandemic. In economic news, the International Monetary Fund has said that Covid might exacerbate the narrowing of global current account imbalances which was happening due to trade slowdown in 2019. Watch the full video for the other updates on the spread of the Sars-CoV-2 coronavirus.
Credit: HT Digital Content Duration: 02:41Published
Speaking on phase-III trials of the COVID-19 vaccine, Uttar Pradesh Health Minister Jai Pratap Singh on September 29 said Bharat Biotech will involve 3,000 people from the state- 1,500 each from Lucknow and Gorakhpur. He said, "Phase-III trials of the COVID-19 vaccine being developed by Bharat Biotech will involve 3,000 people- 1,500 each from Lucknow and Gorakhpur."
Indian Council of Medical Research second Sero Survey report revealed that considerable population still vulnerable to COVID-19, said Health Ministry Secretary Rajesh Bhushan on September 29. "ICMR's..